Crescendo Health Names David Strutton PhD as Chief Scientific Officer
Crescendo Health has appointed David Strutton, PhD, as its new Chief Scientific Officer (CSO). In this role, Dr. Strutton will lead the company's scientific strategy and evidence generation frameworks to advance patient-centric clinical research.
Dr. Strutton brings decades of experience in clinical research, real-world evidence (RWE), and health economics. He has led transformative scientific initiatives at Merck and Pfizer, including establishing Merck's Center for Observational and Real-World Evidence (CORE) and spearheading integrated evidence strategies to support global access to Merck's innovations.
'Dave's deep scientific rigor and long-standing leadership in observational research make him the ideal leader to advance our methodologies,' said Sam Roosz, Co-Founder and CEO of Crescendo Health. 'As clinical development increasingly relies on continuous, patient-consented real-world data, Dave's expertise will ensure our platform delivers the highest standard of scientific integrity.'
Crescendo Health builds data infrastructure designed to power the future of clinical research. By enabling secure, patient-consented access to comprehensive longitudinal health records and real-world data, Crescendo Health helps life sciences organizations generate evidence more quickly and efficiently.